Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Interferon labeling

Executive Summary

Avonex (interferon beta-1a) marketer Biogen expects to meet with FDA in the second quarter regarding the agency's proposal for an interferon class black box warning. "Alpha interferon is used at different dosing ranges and is used to treat patients with different diseases than multiple sclerosis, so it is conceivable that the safety profile will differentiate from that of the beta interferon," VP-Medical Research Burt Adelman, MD, said April 12. FDA notified alpha and beta interferon manufacturers that the warning should be similar to that found in labeling for Schering-Plough's Peg-Intron (1"The Pink Sheet" March 5, In Brief)

You may also be interested in...

Interferon labeling

Manufacturers of alpha and beta interferon products are requested to submit revised labeling with a black box warning in a Feb. 26 letter from the Center for Biologics Evaluation & Research. The revised labeling should indicate the potential for life-threatening neuropsychiatric, autoimmune, ischemic and infectious disorders, CBER says. The black box will be similar to the warning found in labeling for Schering-Plough's PEG-Intron (1"The Pink Sheet" Jan. 29, p. 16)

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts